Real Challenges. Real Solutions.
Precision therapies for genetically defined diseases
Who We Are

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

Opportunity for Impact
Millions of people around the world are living with a genetically defined disease.
Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases.

For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.

Advancing Best-in-Class
Precision Therapies
At Cogent, we start with the end in mind – with the goal of delivering meaningful therapies that improve human health. We focus on diseases where the cause is well understood and is directly linked to a genetic mutation, providing a path forward to develop novel precision therapies.
Explore
Discovering
New Solutions
We have built a world-class discovery organization in Boulder, Colorado, focused on pioneering best-in-class, small molecule therapeutics to improve upon existing drugs with clear limitations and safety concerns, with the goal of creating new breakthroughs for diseases where others have been unable to find adequate solutions.
Explore
Our People,
Our Promise
Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.
Explore
Latest News
June 11, 2025
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Today we announced it has secured a debt financing facility of up to $400 million with credit funds managed by SLR Capital Partners, LLC (“SLR”).
May 29, 2025
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Today we announced its presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET.
May 6, 2025
Cogent Biosciences Reports First Quarter 2025 Financial Results
Today we provided a business update and announced financial results for the first quarter ended March 31, 2025.
Scroll to Top
All Categories
lead-Cole-P
Cole Pinnow

Chief Commercial Officer

Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical industry, with a specific focus on oncology. Before joining Cogent as Chief Commercial Officer, he served at Pfizer as the Global Franchise Lead for its Genitourinary, Lung and Breast Oncology Businesses. In this role, he oversaw the global launch and lifecycle strategy for Xtandi® + Talzenna® in mCRPC. Before that, he was President of Pfizer Canada where he was accountable for the company’s operations within the country, including sales, marketing, access and government relations. He was also VP of a US commercial business unit which had tremendous growth under his leadership. Prior to working at Pfizer, Cole held management positions at both Hospira, Inc., a global pharmaceutical and medical device company, in global pharmaceuticals, global marketing and commercial development. He holds an MBA from the University of Chicago Booth School of Business, a Master of Science degree in Microbiology from Iowa State University, and a Bachelor’s Degree in Biology from St. Olaf College. In his spare time, Cole enjoys swimming, hiking and skiing.